Large Science Models:

A General Framework for Generative Modeling of Microbiome-Metabolome systems

Ishanu Chattopadhyay, PhD

Assistant Professor of Biomedical Informatics & Computer Science

University of Kentucky

What is a healthy Microbiome/ Metabolome?

Can gut microbiota pre-empt developmental deficits?

High Abundance Classes

Complex Interdependecies Exist over time and taxonomic strata

quantized output levels

Can microbial assay from gut actionably

pre-empt developmental deficit?

Study Set-up

Predicting neurodevelopmental deficits

Forecasting ecosystem trajectories

Build classifiers

Ability to "fill in" missing data is equivalent to making trajectory forecasts

Forecast ecosystem fluctuations

Forecasting of class abundance variations both

in-sample (\( R^2 \ge 95\%\))

and out-of sample (\(R^2\ge 72\%\))

Forecasting of class abundance variations both

in-sample (\( R^2 \ge 95\%\))

and out-of sample (\(R^2\ge 72\%\))

Building classifier based on LSM metric

moving the top drivers impact risk of deficit maximally

Understanding Key Drivers via LSM perturbations

No transplantation is guaranteed to work reliably

Predicted to reduce

risk reliably

Predicted to reduce

risk reliably

IBD Metabolomics: Preliminary Results

Dataset from Metabolomics Workbench

Study ID ST000923
Study Title Longitudinal Metabolomics of the Human Microbiome in Inflammatory Bowel Disease
Institute Broad Institute of MIT and Harvard
Last Name Avila-Pacheco
First Name Julian
Submit Date 2017-11-14
Num Groups 3
Total Subjects 546
Num Males 276
Num Females 270
Analysis Type Detail LC-MS

State-of-art microbiome based Classification  (~10 species) *

IBD vs UC 0.82
IBD vs CD 0.76

*Zheng, J., et al. (2024). Noninvasive, microbiome-based diagnosis of inflammatory bowel disease. Nature Medicine, 30(12), 3555–3567. https://doi.org/10.1038/s41591-024-03280-4

IBD vs non IBD 0.85

Gut-Metabolome based Classification  (~36 metabolites) *

Application 2

Metabolomics

LSM model

  • No. parameters: 70 million
  • Out of sample n=150
  • Uses all names and unnamed metabolites (>81K features)
AUC (out of sample)
Healthy vs IBD 96.1%
Healthy vs UC 92%
UC vs CD 99%
Healthy vs CD 99%

Metabolomics

LSM model

  • No. parameters: 70 million
  • Out of sample n=150
  • Uses all names and unnamed metabolites (>81K features)
AUC (out of sample)
Healthy vs IBD 96.1%
Healthy vs UC 92%
UC vs CD 99%
Healthy vs CD 99%

Metabolomics

Insight: the discriminating hypersurface is 2d (almost 1d)

Number of metabolites5,28085% untargeted metabolites
Number of parameters4,002,306
Average Tree Depth38.62
Number of constraints inferred108,884~83% involve untargeted metabolites
Number of samples used180 (no clinical phenotype information used)
  • Using all samples of metabolite profiles

  • Not using clinical phenotypes and replicates

Application 3

ASD Metabolics: Preliminary Results

R_{\mathcal A}(y) := \|L(y)\|_2 = \left( \sum_{k=1}^K \bigl[-\log \Pr(a_k\to y)\bigr]^2 \right)^{1/2}

ASD Metabolics: Preliminary Results

ASD sample profile

ASD samples from same patient

sample profile of new patient \(y\)

Pr(a \rightarrow y)

Need one patient!

Predictive Performance

AUCSensitivity at 95% spec
LSM92.7%74%
MCHAT/F67%39%
ADOS-290-97%85%

getting close to the gold standard

1 false positive 

1 false negative

10% flag in TBD (expected 8.3% positives)

Predictive Performance

Top risk drivers mapped to known pathways

P_x(m_j) = \frac{\partial R(x)}{\partial m_j}

Patient specific driver profile

\displaystyle P(m_j) = \frac{1}{N} \sum_x P_x(m_j)

Average driver profile

Top 30 risk drivers (targeted met.)

A New Paradigm of AI-driven Discovery in Metabolome Biology

Copy of LSM-metabolomics

By Ishanu Chattopadhyay

Copy of LSM-metabolomics

DARPA-EA-25-02-05-MAGICS-PA-025

  • 66